Akebia Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 194

Employees

  • Stock Symbol
  • AKBA

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.47
  • (As of Friday Closing)

Akebia Therapeutics General Information

Description

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Contact Information

Website
www.akebia.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 245 First Street
  • Suite 1400
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Managed Care
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 245 First Street
  • Suite 1400
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akebia Therapeutics Stock Performance

As of 13-Nov-2026, Akebia Therapeutics’s stock price is $0.47. Its current market cap is $132M with 278M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.47 $0.50 $0.36 - $1.83 $132M 278M 8.13M -$0.17

Akebia Therapeutics Financials Summary

As of 30-Sep-2026, Akebia Therapeutics has a trailing 12-month revenue of $197M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 154,359 313,372 429,106 244,775
Revenue 197,197 236,196 160,180 194,623
EBITDA (26,114) 21,727 (13,721) (8,266)
Net Income (44,560) (5,345) (69,410) (51,925)
Total Assets 342,127 376,565 220,670 241,703
Total Debt 60,491 51,798 47,640 48,121
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Akebia Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Akebia Therapeutics‘s full profile, request access.

Request a free trial

Akebia Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Akebia Therapeutics‘s full profile, request access.

Request a free trial

Akebia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business
Pharmaceuticals
Cambridge, MA
194 As of 2025

San Diego, CA
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akebia Therapeutics Competitors (68)

One of Akebia Therapeutics’s 68 competitors is Travere Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Travere Therapeutics Formerly VC-backed San Diego, CA
Calliditas Therapeutics Formerly VC-backed Stockholm, Sweden
AB Science Formerly Accelerator/Incubator backed Paris, France
Mesoblast Corporation Melbourne, Australia
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 68 competitors. Get the full list »

Akebia Therapeutics Patents

Akebia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024407543-A1 Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use Pending 19-Dec-2023
EP-4828662-A1 Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use Pending 19-Dec-2023
WO-2025137158-A1 Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use Inactive 19-Dec-2023
AU-2024373907-A1 Treatment of anca-associated vasculitis Pending 30-Oct-2023
EP-4801531-A1 Treatment of anca-associated vasculitis Pending 30-Oct-2023 A61P13/12
To view Akebia Therapeutics’s complete patent history, request access »

Akebia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akebia Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Akebia Therapeutics‘s full profile, request access.

Request a free trial

Akebia Therapeutics Investments & Acquisitions (4)

Akebia Therapeutics’s most recent deal was a Corporate Asset Purchase with Q32 Bio (Phase 2 Complement Inhibitor Adx-097) for . The deal was made on 01-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Q32 Bio (Phase 2 Complement Inhibitor Adx-097) 01-Dec-2024 Corporate Asset Purchase Buildings and Property
Cyclerion Therapeutics (Rights to Develop and Commercialize Praliciguat) 04-Jun-2021 Corporate Asset Purchase Buildings and Property
Keryx Biopharmaceuticals 13-Dec-2018 Merger/Acquisition Pharmaceuticals
Janssen Pharmaceutica (hypoxia-inducible factor) 13-Feb-2017 Corporate Asset Purchase Buildings and Property
To view Akebia Therapeutics’s complete investments and acquisitions history, request access »

Akebia Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

29.55 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Akebia Therapeutics’s complete esg history, request access »

Akebia Therapeutics FAQs

  • When was Akebia Therapeutics founded?

    Akebia Therapeutics was founded in 2007.

  • Where is Akebia Therapeutics headquartered?

    Akebia Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Akebia Therapeutics?

    Akebia Therapeutics has 194 total employees.

  • What industry is Akebia Therapeutics in?

    Akebia Therapeutics’s primary industry is Pharmaceuticals.

  • Is Akebia Therapeutics a private or public company?

    Akebia Therapeutics is a Public company.

  • What is Akebia Therapeutics’s stock symbol?

    The ticker symbol for Akebia Therapeutics is AKBA.

  • What is the current stock price of Akebia Therapeutics?

    As of 13-Nov-2026 the stock price of Akebia Therapeutics is $0.47.

  • What is the current market cap of Akebia Therapeutics?

    The current market capitalization of Akebia Therapeutics is $132M.

  • What is Akebia Therapeutics’s current revenue?

    The trailing twelve month revenue for Akebia Therapeutics is $197M.

  • Who are Akebia Therapeutics’s competitors?

    Travere Therapeutics, Calliditas Therapeutics, AB Science, Mesoblast, and Gilead are some of the 68 competitors of Akebia Therapeutics.

  • What is Akebia Therapeutics’s annual earnings per share (EPS)?

    Akebia Therapeutics’s EPS for 12 months was -$0.17.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process